Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $84 from $81 and keeps a Hold rating on the shares. The firm said its Q3 results were led by TAVR as the company benefited from increased awareness of aortic stenosis, driven by the stream of clinical data and podium presentations from its asymptomatic work; but likely still isn’t treating asymptomatic patients, due to coverage limitations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences upgraded to Outperform at Raymond James
- Edwards Lifesciences Reports Strong Earnings and Growth
- Edwards Lifesciences price target raised to $92 from $88 at Evercore ISI
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs
- Edwards Lifesciences price target raised to $95 from $89 at RBC Capital